Publications by authors named "H Harada"

Utility values of responders and nonresponders are essential inputs in cost-effectiveness studies of radiation therapy for painful bone metastases but, to our knowledge, they have not been reported separately. We sought to determine the utility values of responders and nonresponders using data from a prospective observational study on bone metastases. The original prospective observational study was conducted at 26 centers in Japan.

View Article and Find Full Text PDF

Objective: This study aimed to evaluate the role of the chromodomain helicase DNA-binding protein 3 (CHD3) in tooth morphogenesis in Chd3 knockout mice.

Methods: Chd3 knockout mice were generated using the CRISPR-Cas9 method. Mandibular first molars were extracted from the mice and their littermates and morphometrically analyzed.

View Article and Find Full Text PDF

Objectives: There is limited consensus on resectability criteria for Stage IIIA-N2 non-small cell lung cancer (NSCLC). We examined the patient characteristics, N2 status, treatment decisions, and clinical outcomes according to the treatment modality for Stage IIIA-N2 NSCLC in Japan.

Materials And Methods: Patients with Stage IIIA-N2 NSCLC in Japan were consecutively registered in the SOLUTION study between 2013 and 2014.

View Article and Find Full Text PDF

Background: Gastrectomy for gastric cancer with duodenal invasion poses an oncological (high positive rate of resection line infiltration) and a surgical (high risk of duodenal fistula) challenge. The purpose of this study was to validate the safety of gastrectomy for gastric cancer with duodenal invasion.

Methods: We included 82 patients with distal gastric cancer who underwent gastrectomy and reconstruction via the Bill-II or R-Y procedure at Kobe University Hospital between 2011 and 2021 were retrospectively reviewed.

View Article and Find Full Text PDF

Background: This study aimed to compare the efficacy and safety of baricitinib in patients with rheumatoid arthritis (RA) receiving different doses based on renal function.

Methods: We conducted a retrospective study within the JAK Study Group, involving 23 facilities in Fukuoka Prefecture, examining patients treated with baricitinib for RA. Patients were categorized into two dose groups: 4 mg with normal/mild renal dysfunction and 2 mg with moderate renal dysfunction.

View Article and Find Full Text PDF